All News
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read Article
The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read Article
EULAR Revised Recommendations for Fibromyalgia
The European League Against Rheumatism (EULAR) recommendations for fibromyalgia (FM) management were published in 2007 and largely had recommendations based on expert opinion’. These guidelines were updated in May of 2015 after a systematic reviews and meta-analyses of the data.
Read Article
Patient and Provider Education Fails to Improve Osteoarthritis Outcomes
A randomized trial of 537 knee osteoarthritis (OA) patients in the Duke Healthcare system has shown that patient- and provider interventions were no better than the usual standard of care.
Read Article
Rituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Read Article
The RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read Article
Less Education Yields Higher Cardiovascular Risk
Similar to the findings in rheumatoid arthritis, lower levels of education can have predictable negative consequences. And the reasons for more heart attacks with lower educational levels is not entirely clear.
Read Article
Do Exercise ‘Weekend Warriors’ Lower Their Risk of Death?
Is being a “weekend warrior” and cramming the recommended amount of weekly physical activity into one or two sessions associated with lower risks for death?
A new article published online by JAMA Internal Medicine suggests that compared with inactive adults, weekend warriors who performed the recommended amount of 150 minutes of moderate or 75 minutes of vigorous activity in one or two sessions per week had lower risks for death from all causes, cardiovascular disease (CVD) and cancer.
Weight Loss Improves Psoriasis
Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition.
Read Article
The RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read Article
Modest Benefits with Intraarticular Corticosteroids in Knee Osteoarthritis
The current online edition of JAMA examines the evidence from 27 clinical trials and 1767 patients to assess the impact of intra-articular corticosteroids in patients with knee osteoarthritis (OA).
A Link Between Periodontal Disease and Rheumatoid Arthritis
Research from Johns Hopkins reports that rheumatoid arthritis (RA) patients with periodontitis exhibited patterns of autoantigen hypercitrullination similar to that seen in RA. Results published in Science Translational Medicine showed that Aggregatibacter actinomycetemcomitans can produce hypercitrullination of patient neutrophils, indicating its possible role in triggering RA. (Citation source: http://buff.ly/2hZTBG8)
Read Article
Osteoporosis 2016 Year in Review - No new drug approvals, and a crisis in care
No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.
Read Article
RheumNow Week in Review – 16 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Read Article
EULAR 2016 Recommendations on Early Arthritis
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Read Article
Supreme Court Declines Biosimilar Patent Dispute
The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.
Read Article
RheumNow Week in Review – 9 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com.
Read Article
The RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read Article
CURES Act : House Passes Largest Bill Since Obamacare
The 21st Century Cures Act has become one of the most-lobbied health care bills in recent history, with nearly a half billion dollars being spent on both sides - those for and against the bill.
Read Article
